Why the study?
Does apixaban reduce major bleeding, thromboembolic events, and mortality compared with warfarin in patients with ESKD and AF on dialysis?
Does apixaban reduce major bleeding, thromboembolic events, and mortality compared with warfarin in patients with ESKD and AF on dialysis?
Apixaban, particularly at the standard 5 mg twice daily dose, may be associated with lower risks of major bleeding, thromboembolism, and mortality compared to warfarin in dialysis patients with ESKD and AF.
Answers are grounded in this paper and cite their sources.
Apixaban may be considered over warfarin in dialysis patients with AF; leaves open confirmation in randomized trials before practice change.
Among patients with ESKD and AF on dialysis, apixaban use may be associated with a lower risk of major bleeding compared with warfarin, with a standard 5 mg twice a day dose also associated with reductions in thromboembolic and mortality risk.
No takes yet. Share an insight, caveat, or question.
Siontis et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: